Does Florida Blue Cover Wegovy?
The verdict
Not Covered on most plans
Florida Blue explicitly excludes weight-loss drugs, including Wegovy for weight management, under its commercial GLP-1 policy. Appealing this exclusion will not succeed — it is a benefit exclusion, not a medical-necessity denial. The only insured path is the cardiovascular risk reduction indication for members with established CVD; Medicare members can access weight-loss coverage via the GLP-1 Bridge at $50/month from July 1, 2026.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Florida Blue (Blue Cross Blue Shield of Florida) using your member ID.
Key facts
Florida Blue excludes weight-loss drugs, including Wegovy for weight management, under its commercial GLP-1 policy — a benefit exclusion that cannot be overridden by prior-authorization paperwork.
Florida Blue commercial GLP-1 policy
Florida Medicaid does not cover GLP-1s for obesity; as of January 2026, only 13 state Medicaid programs cover GLP-1s for obesity treatment.
KFF, Medicaid Coverage of and Spending on GLP-1s, 2026
Wegovy is FDA-approved for chronic weight management (BMI 30+, or 27+ with a weight-related comorbidity) and for cardiovascular risk reduction in adults with established CVD — it is a weight-loss and CV drug, not a diabetes drug.
FDA, Wegovy (semaglutide) prescribing information
Medicare vs. commercial coverage
Whether Florida Blue (Blue Cross Blue Shield of Florida) covers Wegovy depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Medicare Part D cannot cover Wegovy for weight loss by federal statute — no Florida Blue formulary decision changes this. For Medicare members with established cardiovascular disease who are overweight or obese, the cardiovascular risk reduction indication is coverable under Part D with prior authorization. The Medicare GLP-1 Bridge (launching July 1, 2026, through December 31, 2027) provides weight-loss access to Wegovy at a fixed $50 per month copay outside Part D — this $50 does not count toward the deductible, TrOOP, or the $2,100 OOP cap. Bridge eligibility requires provider attestation: BMI 35 or higher; or BMI 30 or higher with heart failure, uncontrolled hypertension, or CKD; or BMI 27 or higher with prediabetes, prior heart attack, prior stroke, or symptomatic PAD. Members already on a Part D-covered GLP-1 are ineligible for the Bridge. Medicare beneficiaries cannot use the NovoCare savings card (federal anti-kickback rules).
Commercial / Employer
Group & marketplace plans
Florida Blue excludes weight-loss drugs, including Wegovy for weight management, under its commercial GLP-1 policy. This applies to employer-sponsored and ACA/individual plans. Florida Medicaid does not cover GLP-1s for obesity. Because this is a benefit exclusion — not a medical-necessity denial — prior-authorization paperwork will not change the outcome; the drug category is simply absent from the covered benefit. Members seeking treatment for established cardiovascular disease may ask their provider about the cardiovascular risk reduction indication, which is a separate coverage consideration. Verify current plan details on the Florida Blue drug-lookup tool.
Your cost, three ways
What Wegovy actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
$1,349 per month (Novo Nordisk published list price for a 28-day supply)
List price with no coverage — before any manufacturer savings card.
With coverage
Medicare CV indication: Part D cost-share depends on plan tier and benefit phase; $2,100 beneficiary OOP cap applies in 2026. Medicare Bridge (weight loss, from 7/1/2026): fixed $50 per month copay outside Part D — does not count toward the deductible, TrOOP, or the $2,100 cap. Commercial weight-loss Wegovy: not covered; cash only.
Typical monthly copay once prior authorization is approved.
Bridge program
NovoCare self-pay program: approximately $199 per month for starting doses (0.25/0.5 mg, first two fills through December 31, 2026), then approximately $349 per month for standard injection doses. The NovoCare commercial savings card ($25/month) is not applicable to Florida Blue's excluded weight-loss use. Medicare/Medicaid members cannot use the savings card. From January 1, 2027, Novo Nordisk has announced a list-price reduction to approximately $675 per month; the IRA-negotiated Maximum Fair Price of $274 per 30-day supply also takes effect January 1, 2027.
Reduced copay through the assistance program, where eligible.
All figures are estimates. Confirm with Florida Blue member services or the plan drug-lookup tool. Cash prices may vary by pharmacy.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Check the Florida Blue drug-lookup tool to confirm current exclusion
Visit the Florida Blue member portal and search for Wegovy (semaglutide 2.4 mg) under your specific plan. Confirm that weight-loss drugs are excluded under your plan's benefit design. If you have a self-funded employer plan, ask HR whether anti-obesity drugs were added to your benefit — self-funded groups occasionally differ.
- 2
Ask your provider about the cardiovascular indication
If you have established cardiovascular disease and are overweight or obese, ask your prescriber whether Wegovy's FDA-approved cardiovascular risk reduction indication applies to your case. This is the only insured path under most Florida Blue plans and under Medicare Part D. Your provider would need to document your qualifying CVD diagnosis.
- 3
If you are a Medicare member, ask your provider about GLP-1 Bridge eligibility
Starting July 1, 2026, the Medicare GLP-1 Bridge provides weight-loss access to Wegovy at $50 per month through December 31, 2027, outside the Part D benefit. Your provider must attest to your BMI and qualifying conditions at initiation. Verify eligibility criteria — members already on a Part D-covered GLP-1 are excluded.
Options if Florida Blue (Blue Cross Blue Shield of Florida) won't cover Wegovy
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Cardiovascular indication (Medicare Part D or qualifying commercial)
Wegovy is FDA-approved for cardiovascular risk reduction in adults with established CVD who are overweight or obese. This indication can be covered under Medicare Part D and potentially certain Florida Blue commercial plans with prior authorization — distinct from the excluded weight-loss benefit.
Medicare GLP-1 Bridge
Launching July 1, 2026, the Bridge offers eligible Medicare members Wegovy for weight loss at $50 per month through December 31, 2027, outside Part D. Eligibility criteria apply; members already on a Part D-covered GLP-1 are ineligible.
NovoCare self-pay program
Novo Nordisk's NovoCare program offers a self-pay price of approximately $199 per month for starting doses (first two fills through December 31, 2026), then approximately $349 per month for standard injection doses. Not available to Medicare or Medicaid beneficiaries. Verify current pricing at novocare.com.
Compounded semaglutide
Compounded semaglutide, available through licensed telehealth platforms, does not require insurance prior authorization. Starting from $49 per month. Compounded semaglutide is not the same medication as Wegovy and has not been approved by the FDA.
These options are listed for information only — your own clinician decides what is appropriate for you.
❓Frequently Asked Questions
No. Florida Blue explicitly excludes weight-loss drugs, including Wegovy for weight management, under its commercial GLP-1 policy. This is a benefit exclusion — not a prior-authorization denial — which means submitting PA paperwork will not change the outcome. Florida Medicaid also does not cover GLP-1s for obesity. The only insured route for most members is the cardiovascular risk reduction indication, available with prior authorization for members with established CVD.
Appealing a benefit exclusion is generally not productive. When a drug category is excluded from the plan's covered benefits, it means the employer or plan chose not to include it — that is not a medical-necessity determination that can be reversed through an appeal. A prior-authorization denial, by contrast, is a coverage decision that can be challenged. Florida Blue's weight-loss drug exclusion falls into the former category. If you have a self-funded employer plan, ask HR whether anti-obesity drugs were included in your specific benefit design.
Florida Blue Medicare Part D cannot cover Wegovy for weight loss by federal statute — this is a statutory exclusion affecting all Medicare plans. The cardiovascular risk reduction indication is coverable under Part D with prior authorization for members with established CVD who are overweight or obese. Starting July 1, 2026, eligible Medicare members may access Wegovy for weight loss at $50 per month via the Medicare GLP-1 Bridge, which operates outside Part D. Verify current plan details with Florida Blue.
Wegovy's published list price is $1,349 per month for a 28-day supply. Novo Nordisk's NovoCare self-pay program offers approximately $199 per month for starting doses (first two fills through December 31, 2026), then approximately $349 per month for standard injection doses. The NovoCare commercial savings card (as low as $25/month) is not applicable where the plan excludes Wegovy for weight loss. From January 1, 2027, Novo Nordisk has announced a list-price reduction to approximately $675 per month.
Both Florida Blue and BCBS of Michigan exclude weight-loss GLP-1 coverage, but the mechanics differ. BCBS of Michigan ended coverage for fully insured large-group plans effective January 1, 2025, citing a cost increase from $8 million to nearly $200 million over three years. Florida Blue's exclusion operates under a standing commercial GLP-1 policy. In both cases, the weight-loss exclusion is a benefit carve-out, not a formulary tier decision — verify your specific plan's current status on the respective drug-lookup tool.
Related Articles
Does BCBS North Carolina Cover Wegovy? 2026 | Curex
BCBS North Carolina: NC State Health Plan dropped weight-loss GLP-1s in 2024; NC Medicaid removed obesity coverage October 2025. Verify your specific plan.
Read moreDoes BCBS of Arizona Cover Wegovy? 2026 Guide | Curex
BCBS of Arizona covers Wegovy only where your employer opted in; formulary not published. Verify via drug-lookup and confirm with HR first.
Read moreDoes Blue Cross Blue Shield of Illinois Cover Wegovy? | Curex
BCBS Illinois (HCSC) covers Wegovy only where your employer opts in. ACA plans exclude it. Formulary not public — verify on your plan's drug-lookup tool.
Read moreDoes BCBS Alabama Cover Wegovy? 2026 Guide | Curex
BCBS Alabama Wegovy coverage is employer-dependent and unpublished. Alabama Medicaid excludes obesity GLP-1s. How to verify your specific plan.
Read moreDoes BCBS Michigan Cover Wegovy? 2026 Coverage Guide | Curex
BCBS Michigan ended weight-loss GLP-1 coverage on fully insured plans in 2025. Self-funded groups may opt in. Michigan Medicaid covers Wegovy as preferred.
Read moreDoes Blue Cross MN Cover Wegovy? 2026 Employer Guide | Curex
Blue Cross MN covers Wegovy only where your employer bought the anti-obesity benefit. Not published at drug level — check plan drug lookup and ask HR.
Read moreWhether or not Florida Blue covers Wegovy, there's a path that skips insurance
Florida Blue explicitly excludes Wegovy for weight loss, so most members searching this question are facing self-pay from the start. Compounded semaglutide from $49/mo (compounded tirzepatide from $149/mo) is available at Curex — no insurance, no prior authorization. Compounded semaglutide is not the same medication as Wegovy. Prescription required, subject to provider review.
- Medication + free shipping
- 24/7 provider access
- Medical intake & prescription review
Compounded semaglutide and tirzepatide are not the same medications as Wegovy and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.
This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Florida Blue (Blue Cross Blue Shield of Florida) before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Wegovy and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.